Hikma Pharmaceuticals | Sustainability & Chart

GB00B0LCW083

Basic information on Hikma Pharmaceuticals

Location: United Kingdom

Industry: Manufacturing

Website

Impact Score

Description Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of branded and non-branded generic medicines across a variety of therapeutic areas.

Hikma Pharmaceuticals Sustainability Performance

Climate

26%

Renewable Energy

Hikma Pharmaceuticals obtains 18% of its energy from renewable energies. Target value per method: min. 100%

Greenhouse Gas Emissions

Hikma Pharmaceuticals emits 3,1 times its CO₂ budget of 45,594 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Supply Chain

Taking into account the entire supply chain, Hikma Pharmaceuticals emits 22 times its CO₂ budget of 45,594 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Recycling and Recovery of Waste

Hikma Pharmaceuticals recycles 34,5% of its waste. Target value per method: min. 75%

Society

48%

Union Formation and Collective Bargaining Power

No data available for Hikma Pharmaceuticals. Target value per method: min. 80%

CEO Pay Ratio

CEO Said Darwazah earns 42 times the average salary of employees. Target value per method: max. 20 times

Employee Turnover Rate

Hikma Pharmaceuticals has an employee turnover rate of 11%. Target value per method: max. 5%

Harassment and Discrimination at the Workplace

Hikma Pharmaceuticals meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria

Gender

69%

Women on Board

Hikma Pharmaceuticals has 44,4% women across its top leadership and supervisory bodies. Target value per method: min. 40%

Gender Pay Gap

No data available for Hikma Pharmaceuticals. Target value per method: max. 3%

Women in Management

Hikma Pharmaceuticals employs 31% female managers. Target value per method: min. 40%

Glass Ceiling

The proportion of women in senior management at Hikma Pharmaceuticals is 86,7% of the proportion of women in the overall workforce. Target value per method: min. 90%

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

Renewable Energy

Greenhouse Gas Emissions

Supply Chain

Waste Recycling

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

Compare Hikma Pharmaceuticals with ...

Hikma Pharmaceuticals

?

Impact Score

Climate

Society

Gender

26%

48%

69%

Hikma Pharmaceuticals

?

Impact Score

Climate

Society

Gender

Sources of sustainability performance

Metric	Value	Unit	Year	PDF Name	PDF Page
CEO Pay Ratio
Total wages paid	692	$m	2025	hikma_ar25_interactive.pdf	102
CEO salary	3 078 000	$	2025	hikma_ar25_interactive.pdf	62
Number of employees	9 381	people	2025	Hikma_SR2025.pdf	81
CEO name	Said Darwazah		2025	hikma_ar25_interactive.pdf	78
Employee Turnover Rate
Voluntary employee turnover	11	%	2025	Hikma_SR2025.pdf	82
Glass Ceiling
Women in workforce	3 354	Women	2025	Hikma_SR2025.pdf	83
Women in management	31	%	2025	Hikma_SR2025.pdf	83
Number of employees	9 381	people	2025	Hikma_SR2025.pdf	81
Greenhouse Gas Emissions
Number of employees	9 381	people	2025	Hikma_SR2025.pdf	81
Scope 1 emissions	46 742	tCO2e	2025	hikma_ar25_interactive.pdf	32
Scope 2 emissions, location based	92 575	tCO2e	2025	hikma_ar25_interactive.pdf	32
Harassment and Discrimination at the Workplace
Anti-discrimination policy	Yes		2025	code-of-conduct-eng-2026.pdf	9
Retaliation safeguards	Yes		2025	code-of-conduct-eng-2026.pdf	9
Incident notification mechanism	Yes		2025	code-of-conduct-eng-2026.pdf	6
Confidentiality mechanisms	Yes		2025	code-of-conduct-eng-2026.pdf	6
Renewable Energy
Total renewable energy consumption	18	%	2025	Hikma_SR2025.pdf	77
Supply Chain
Number of employees	9 381	people	2025	Hikma_SR2025.pdf	81
Scope 3 emissions	863 128	tCO2e	2025	Hikma_SR2025.pdf	87
Scope 1 emissions	46 742	tCO2e	2025	hikma_ar25_interactive.pdf	32
Scope 2 emissions, location based	92 575	tCO2e	2025	hikma_ar25_interactive.pdf	32
Recycling and Recovery of Waste
Total waste generation	12 301	Tonnes	2025	Hikma_SR2025.pdf	91
Waste recycled	4 248	Tonnes	2025	Hikma_SR2025.pdf	91
Women on Board
Women on supervisory board	5	people	2025	hikma_ar25_interactive.pdf	51
Executive board size	8	people	2025	hikma_ar25_interactive.pdf	51
Women on executive board	3	people	2025	hikma_ar25_interactive.pdf	51
Supervisory board size	10	people	2025	hikma_ar25_interactive.pdf	51
Women in Management
Women in management	31	%	2025	Hikma_SR2025.pdf	83

Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

Find more sustainable companies

Home Find Companies & ETFs Learn to invest Academy Glossary Our Method

Imprint Privacy Policy GTC FAQContact Us

© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev